UroGen Pharma Ltd. (URGN)
| Market Cap | 1.80B +131.1% |
| Revenue (ttm) | 188.73M +100.3% |
| Net Income | -97.64M |
| EPS | -1.97 |
| Shares Out | 48.88M |
| PE Ratio | n/a |
| Forward PE | 24.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,895,594 |
| Open | 36.97 |
| Previous Close | 36.98 |
| Day's Range | 36.69 - 38.11 |
| 52-Week Range | 15.86 - 50.81 |
| Beta | 1.58 |
| Analysts | Strong Buy |
| Price Target | 60.00 (+62.91%) |
| Est. Earnings | Nov 5, 2026 |
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocal... [Read more]
Financial Performance
In 2025, UroGen Pharma's revenue was $109.79 million, an increase of 21.45% compared to the previous year's $90.40 million. Losses were -$153.49 million, 21.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price target is $60.0, which is an increase of 62.91% from the latest price.
News
UroGen Pharma falls -12.8%
UroGen Pharma (URGN) is down -12.8%, or -$5.20 to $35.50.
UroGen Pharma management to meet with Piper Sandler
Meeting to be held on September 28-30 hosted by Piper Sandler.
UroGen Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The discussion highlighted strong early demand for Zusduri, with significant room for physician adoption and growth, especially in community settings. Key pipeline milestones include UGN-103's upcoming data and approval, UGN-104's trial progress, and the initiation of UGN-501 studies, supporting long-term expansion.
UroGen Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
RTGel-based therapies are driving growth in urothelial cancer markets, with Zusduri showing strong early commercial performance and unique non-surgical positioning. Next-gen products like UGN-103 promise operational efficiencies and extended IP, while strategic collaborations and a robust cash position support future expansion.
UroGen Pharma Transcript: Wells Fargo 21st Annual Healthcare Conference
ZUSDURI's launch in non-muscle invasive bladder cancer has driven significant growth, supported by a strong value proposition and expanding prescriber base. Next-generation products and pipeline expansion, including UGN-103, UGN-104, and UGN-501, aim to sustain momentum and broaden the addressable market.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and spec...
UroGen Pharma to Present at Upcoming Investor Conferences
PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's...
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exc...
UroGen Pharma submits UGN-103 NDA to FDA
UroGen Pharma (URGN) announced the submission of a new drug application, or NDA, to the FDA for its investigational drug UGN-103 for intravesical solution. UGN-103 is a next-generation mitomycin formu...
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
PRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma price target raised to $60 from $50 at Oppenheimer
Oppenheimer raised the firm’s price target on UroGen Pharma (URGN) to $60 from $50 and keeps an Outperform rating on the shares. The firm notes the company reported another strong…
UroGen Pharma price target raised to $58 from $42 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on UroGen Pharma (URGN) to $58 from $42 and keeps a Buy rating on the shares. The firm is raising its…
UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on UroGen Pharma (URGN) to $75 from $45 and keeps a Buy rating on the shares. The firm cites the company’s “massive” Q2…
UroGen Pharma price target raised to $60 from $50 at TD Cowen
TD Cowen raised the firm’s price target on UroGen Pharma (URGN) to $60 from $50 and keeps a Buy rating on the shares. The firm says Zusduri growth accelerated 72%…
UroGen Pharma Earnings Call Transcript: Q2 2026
Q2 2026 revenue surged to $72.5M, led by ZUSDURI's rapid adoption and strong community uptake, while JELMYTO remained stable. Pipeline progress, new patents, and expanded investments support a positive long-term outlook, with profitability expected using current capital.
UroGen Pharma Earnings release: Q2 2026
UroGen Pharma released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
UroGen Pharma Quarterly report: Q2 2026
UroGen Pharma has published its Q2 2026 quarterly earnings report on August 5, 2026.
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth Once issued, new U.S. patent is expected to provide protection into July 2044 f...
UroGen Pharma Slides: Corporate presentation
UroGen Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET
UroGen Pharma price target raised to $42 from $32 at Guggenheim
Guggenheim raised the firm’s price target on UroGen Pharma (URGN) to $42 from $32 and keeps a Buy rating on the shares. The firm is revising some of its estimates…
UroGen Pharma price target raised to $50 from $40 at Oppenheimer
Oppenheimer analyst Leland Gershell raised the firm’s price target on UroGen Pharma (URGN) to $50 from $40 and keeps an Outperform rating on the shares. The firm increased its sales…
UroGen Pharma price target raised to $44 from $18 at Goldman Sachs
Goldman Sachs raised the firm’s price target on UroGen Pharma (URGN) to $44 from $18 and keeps a Neutral rating on the shares. Gel-based mitomycin generics in NMIBC – Non-Muscle-Invasive…
UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103
Earlier this morning, the company stated: “UroGen Pharma (URGN) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application no. 18/784,354…